Focus Fund and MD Anderson launch investment fund to support promising investigational cancer therapies in early-stage clinical trials

The Focus Fund GP, LLC, in partnership with The University of Texas MD Anderson Cancer Center, has launched Cancer Focus Fund, LP, an oncology-focused investment fund designed to support the advancement of compelling investigational cancer therapies from late preclinical development through Phase I and Phase Ib/II clinical trials.

Read more

Boehringer Ingelheim and MD Anderson form unique virtual research and development center to rapidly advance new cancer therapies

Boehringer Ingelheim and MD Anderson have announced a new multi-year partnership to conduct collaborative research, combining the drug-development capabilities of MD Anderson with the pipeline of novel medicines from Boehringer Ingelheim.

Read more